Thomas F. Tedder

Vice President | Venture Banking Group, Customers Bank
Denver, Colorado,United States
Find Thomas F. Tedder's Email
Find Thomas F. Tedder's Phone

Who Is Thomas F. Tedder?

Total Experience10 years
CompanyCustomers Bank
CountryUnited States

Dr. Thomas F. Tedder is a highly distinguished figure in the field of immunology, currently serving as the Alter Geller Professor of Immunology in the Department of Immunology at Duke University Medical Center. His research has profoundly impacted our understanding of B lymphocyte (B cell) biology, particularly their development, regulation, and function in both normal immunity and disease states such as autoimmunity and cancer. Dr. Tedder's laboratory has been at the forefront of identifying and characterizing critical cell surface molecules on B cells, including CD19, CD20, CD22, and CD72, as well as the adhesion molecule L-selectin (CD62L). These discoveries have not only illuminated fundamental aspects of immune cell function and trafficking but have also paved the way for innovative immunotherapies. Many of these molecules are now successful targets for treating B cell malignancies, autoimmune diseases, and transplant rejection. His work seamlessly bridges basic immunological research with translational medicine, aiming to develop novel therapeutic strategies.

How Did Thomas F. Tedder's Career Path Shape Their Journey?

Thomas F. Tedder's work history includes a series of influential roles in various companies. Here is a detailed list of his professional journey:

Customers Bank - Vice President | Venture Banking Group(2023 to Present)
Signature Bank - Vice President | Signature Venture Banking Group(2021 to 2023)
Square 1 Bank - AVP Venture Technology Banker - Rocky Mountain(2017 to 2019)

What Are Thomas F. Tedder's Key Achievements?

Alter Geller Professor of Immunology

Holds the prestigious Alter Geller Professorship of Immunology at Duke University Medical Center, recognizing his exceptional contributions and leadership in the field of immunology.

Pioneering Research in B Cell Surface Molecules

Led groundbreaking research in identifying, cloning, and characterizing key B lymphocyte cell-surface molecules including CD19, CD20, CD22, and others. These molecules are crucial for B cell development, activation, and function, and have become major targets for immunotherapies.

Development of Immunotherapies for B Cell Disorders

His foundational work on B cell antigens has been instrumental in the development of numerous successful monoclonal antibody therapies (e.g., Rituximab targeting CD20) and CAR T-cell therapies for B cell leukemias, lymphomas, and autoimmune diseases.

Significant Contributions to L-selectin (CD62L) Research

Made seminal discoveries regarding the L-selectin adhesion molecule, elucidating its critical role in lymphocyte trafficking, leukocyte rolling, and immune cell homing to sites of inflammation and secondary lymphoid organs.

Fellow of the American Association for the Advancement of Science (AAAS)

Elected as a Fellow of the AAAS for his distinguished contributions to the biological sciences, particularly in immunology and the development of B cell-targeted therapies.

Recipient of NIH MERIT Award

Awarded a Method to Extend Research in Time (MERIT) award from the National Institutes of Health (NIH), recognizing his consistent and outstanding research competence and productivity.

What's Thomas F. Tedder's Educational Background?

Bachelor of Science (BS), Economics, Minor: Financial Management

Wilbur O. and Ann Powers College of Business at Clemson University - Year 2011

International Business Law

University of Oxford - Year 2014

Buying Intent Signals for Thomas F. Tedder

Highperformr Signals uncover buying intent and give you clear insights to target the right people at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance

Company Overview

Customers Bank
Total employees1380
HeadquartersWest Reading
Founded1997

Customers Bank is a full-service super-community bank with assets of approximately $22 billion. A member of the Federal Reserve System and an FDIC insured bank, it provides a range of banking and lending services to small and medium-sized businesses, professionals, individuals, and families. Services include commercial and industrial loans, commercial real estate loans, multi-family loans, Small Business Administration (SBA) loans, residential mortgages, and consumer banking products. Customers Bank is a subsidiary of Customers Bancorp, Inc. (NYSE:CUBI), a bank holding company. It's known for its 'high-tech, high-touch' approach, combining advanced technology with personalized customer service.

Customers Bank Stock Information
Customers Bank, Inc. is listed on the NYSE under the ticker symbol CUBI. The company went public on October 9, 2013

Highperformr's free tools for company research

Find contact info

Get verified emails, phone numbers, and LinkedIn profile details

Find similar contacts

Discover contacts with similar roles, seniority, or companies

Perform deep contact research

Uncover insights like skills, work history, social links, and more

Discover, research and enrich contacts with Highperformr — Smarter, Faster

Explore contacts in-depth — from verified emails and phone numbers to LinkedIn activity, job changes, and more — all in one powerful view.

Highperformr AI helps you surface the right people and enrich your CRM with live, accurate contact insights so your teams can connect faster and close smarter.

  • Track signals like job change, promotion, and LinkedIn activity
  • Enrich contacts with verified email, phone, and social data instantly
  • Automate enrichment and updates with powerful workflows
  • Sync enriched contact info directly into your CRM and tools

Thousands of contacts — including decision-makers, influencers, and ICP matches — are just a search away.

Thousands of companies, including, are just a search away.